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Background: Previous studies on the relationship between bone health and metabolic syndrome (MS) have
revealed heterogeneous results. There are limited studies employing bone quantitative ultrasonometry in evaluating
this relationship. This study aimed to determine the relationship between MS and bone health in a group of
Malaysian middle-aged and elderly men using bone quantitative ultrasonometry.
Methods: This cross-sectional study recruited 309 free living Chinese and Malay men aged 40 years and above
residing in Klang Valley, Malaysia. Their demographic and anthropometric data were collected. Their calcaneal speed
of sound (SOS) was measured using a CM-200 bone ultrasonometer. Their blood was collected for the evaluation of
lipid profile, total testosterone and sex hormone-binding globulin. The joint interim MS definition was used for the
classification of subjects. Multiple linear regression analysis was used to assess the association between SOS and
indicators of MS and the presence of MS, with suitable adjustment for confounders.
Results: There was no significant difference in SOS value between MS and non-MS subjects (p > 0.05). The SOS
values among subjects with different MS scores did not differ significantly (p > 0.05). There were no significant
associations between SOS values and indicators of MS or the presence of MS (p > 0.05).
Conclusions: The relationship between bone health and MS is not significant in Malaysian middle-aged and elderly
men. A longitudinal study should be conducted to evaluate the association between bone loss and MS to confirm
this finding.
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Osteoporosis and cardiovascular diseases constitute two
major health problems worldwide [1]. Metabolic syn-
drome (MS) is a cluster of metabolic phenotypes, which
in a whole predicts cardiovascular events better than the
sum of each indicator [2]. Several MS definitions have
been put forward by various organizations, such as the
World Health Organization [3], the International Dia-
betes Federation [4], and the National Cholesterol Edu-
cation Program Adult Treatment Panel III criteria [5].
Recently, a joint interim statement has been introduced* Correspondence: imasoel@ppukm.ukm.edu.my
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unless otherwise stated.to harmonize the MS criteria [6]. Briefly, these criteria
include central obesity, increased blood pressure (BP),
triglyceride (TG) and fasting blood glucose (FBG) levels
and decreased high-density lipoprotein cholesterol (HDL)
level [6].
Deterioration of bone health is a direct consequence
of aging in both men and women [7], but less attention
is given to men [8]. Previous studies have found that
each MS indicators is related to bone health in humans.
Obesity increases mechanical loading and is related to
improved bone health [9]. Proinflammatory cytokines,
leptin and adiponectin secreted by adipocytes can influ-
ence bone metabolism [10]. Hyperlipidemia has been
shown to increase resorption activity in the bone [11]
and lipid peroxidation products can induce oxidativeis is an Open Access article distributed under the terms of the Creative
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increases parathyroid hormone level and urinary calcium
excretion [13,14]. Type I diabetes increases bone mineral
density while type II diabetes decreases it [15].
The presence of metabolic syndrome has been associated
with variations in bone mass measured by dual-energy
X-ray absorptiometry (DEXA) and calcaneal quantitative
ultrasonometry (QUS) in men. However, the results ob-
tained are heterogeneous, whereby positive [16,17], nega-
tive [18] and non-significant [19,20] associations have been
reported. Due to the limited number of studies available,
no conclusive statement can be drawn on whether MS ex-
erts beneficial or adverse effects on bone health in men.
This study aimed to examine the relationship of MS
on bone health in a group of Malaysian Chinese and
Malay men. The calcaneal QUS technique was used be-
cause literatures on the relationship between MS and
bone QUS indices in men were limited. We hope that
this study would provide more evidence on the clinical
impact of MS on bone health in men, which is an issue
deserving more attention.
Material and methods
The current study was conducted as part of the Malaysian
Aging Male Study [21,22]. The recruitment was performed
between September 2009 and September 2011. The sub-
jects recruited were Malaysian Chinese and Malay males,
aged 40 years and above, residing in Klang Valley,
Malaysia. The subjects were invited via advertisements in
major newspapers, radio broadcasts, flyers, public an-
nouncements in community centers and religious places.
The inclusion and exclusion criteria were mentioned
clearly in the invitation. The following subjects were ex-
cluded from this study: (1) those suffering from chronic
bone diseases such as osteoporosis, osteomalacia, Paget’s
disease etc.; (2) those undergoing treatment or taking
medication that might alter bone metabolism, such as sex
hormone replacement, thyroid supplements, thiazide di-
uretics, lithium, glucocorticoids etc.; (3) those with mobil-
ity problems and need walking aids; (4) those undergoing
a major surgery or suffering from a fracture six months
prior to the screening; (5) those unable to complete the
screening process. The subjects participated on their own
volition. They were briefed on the details of this study and
written consent was obtained before the enrollment. The
Research and Ethics Committee of Universiti Kebangsaan
Malaysia Medical Center reviewed and approved the study
protocol (Code: UKM-AP-TKP-09-2009).
The subject answered a detailed questionnaire on their
demographic characteristics. Their age was determined
from the records on their identification cards and their
ethnicity was self-declared. They underwent a physical
examination performed by qualified physicians and their
medical history was taken.The height of the subjects without shoes was deter-
mined using a portable stadiometer (SECA, Hamburg,
Germany) and was recorded to the nearest 0.1 cm. The
weight of the subjects with light clothing without shoes
were determined using a weighing scale (Tanita, Tokyo,
Japan) and was recorded to the nearest 0.1 kg. Their
body mass index (BMI) was calculated as per the con-
vention. Their waist circumference (WC) was measured
using a soft measuring tape midway between the lower
rib margin and the superior border of the iliac crest at
the end of a normal expiration in the standing position.
It was recorded to the nearest 1 cm. Their calcaneal
speed of sound (SOS) was measured using the CM-200
bone ultrasonometer (Furuno, Nishinomiya, Japan). Cali-
bration of the device was carried out at the beginning of
each screening session and the measurement was per-
formed by a trained technician. Three readings were
taken per subject and the average SOS value was used in
the analysis. The short-term in vivo precision of the
bone ultrasonometer was 0.19%. The blood pressure
(BP) of the subjects was determined using a mercury
sphygmomanometer in the sitting position. If the blood
pressure was high, the subjects were requested to rest
for 15 minutes before another reading was taken.
All subjects were required to fast for at least eight
hours before blood collection. Venipuncture was per-
formed by qualified phlebotomists or physicians between
0830 and 1030 hours. Serum was extracted immediately
after the blood collection. Part of the serum was sent
immediately to an accredited laboratory for lipid profile
and total testosterone (TT) evaluation while the rest was
stored at -80°C until analysis. The ADVIA 2400 Chemis-
try Analyzer (Siemens Healthcare Diagnostics, Illinois,
USA) was used to evaluate total cholesterol (TC), trigly-
ceride (TG) and high-density lipoprotein cholesterol
(HDL) levels using enzymatic method. The ADVIA Cen-
taur immunoassay system (Siemens Healthcare Diagnostics,
Illinois, USA) was used to evaluate TT level using direct
chemiluminescent technique. Enzyme-linked immuno-
bsorbent kit (IBL International, Hamburg, Germany) was
used to evaluate the level of sex hormone-binding globulin
(SHBG). The ACCUCHEK portable glucometer (Roche,
Basel, Switzerland) was used to measure fasting blood glu-
cose (FBG) level by the glucose oxidase method.
Definition of MS
Metabolic syndrome was defined using the harmonized
criteria based on the joint interim consensus [6]. Sub-
jects fulfilling at least three out of the five criteria listed
were categorized as MS subjects: (1) WC ≥ 90 cm; (2)
TG ≥ 1.7 mmol/l or on drug treatment for elevated TG;
(3) HDL ≤ 1.0 mmol/l or on drug treatment for reduced
HDL; (4) Systolic BP ≥ 130 mmHg and/or diastolic BP ≥
85 mmHg or on drug treatment for hypertension; (5)
Table 1 The comparison of basic characteristics between
MS and non-MS subjects
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blood glucose.MS (n=190) Non-MS (n=119)
Mean SD Mean SD p-value
Age (years) 55.46 8.86 51.80 9.72 0.001
Height (m) 1.67 0.06 1.67 0.06 0.843
Weight (kg) 72.70 10.19 65.61 11.01 <0.001
BMI (kg/m2) 26.03 3.61 23.77 3.75 <0.001
SOS (m/s) 1511.70 24.12 1513.80 24.04 0.451
WC (cm) 99.70 6.05 95.70 7.80 <0.001
Bpsys (mmHg) 146.88 16.72 132.15 16.46 <0.001
Bpdia (mmHg) 87.48 9.97 80.79 9.53 <0.001
HDL (mmol/l) 1.22 0.25 1.40 0.29 <0.001
TG (mmol/l) 1.85 0.82 1.13 0.50 <0.001
TC (mmol/l) 5.70 1.00 5.72 0.85 0.705
LDL (mmol/l) 3.64 0.90 3.79 0.81 0.066
FBS (mmol/l) 6.43 1.76 5.46 0.63 <0.001*
TT (nmol/l) 17.56 5.95 21.00 7.55 <0.001
SHBG (nmol/l) 47.31 24.72 56.10 31.75 0.008
Smoker (n) 32 - 27 - 0.203†
Non-smoker (n) 158 - 92 -
Malay (n) 53 - 30 - 0.604†
Chinese (n) 137 - 89 -
*Indicates that Mann-Whitney U test is used for analysis. †indicates that Pearson’s
Chi-square is used for analysis. For all other data, independent t-test is used for
analysis.
Abbreviation: BMI Body mass index, Bpdia diastolic blood pressure, Bpsys Systolic
blood pressure, FBG fasting blood glucose, HDL high density lipoprotein
cholesterol, LDL low-density lipoprotein cholesterol, SD standard deviation, SHBG
sex hormone-binding globulin, SOS calcaneal speed of sound, TC total cholesterol,
TG triglycerides, TT total testosterone, WC waist circumference.Statistical analysis
The normality of the data was assessed using Shapiro-Wilk
test with the aid of histograms. Skewed data were log-
transformed and used in the analysis. The level of FBG
could not be normalized; hence it was analyzed using
non-parametric tests. The comparison of the basic charac-
teristics of the subjects was performed using independent
t-test for normally distributed data and Mann-Whitney U
test for FBG. The comparison of SOS values among the
groups based on their MS scores (0-5) was made using a
general linear model (univariate) with adjustment for con-
founders. The associations between SOS and MS, and
each indicator of MS were evaluated using multiple linear
regression analysis. The indicators of MS were first en-
tered as continuous variables and then as dichotomous
variables (1 = the presence of a condition/0 = the absence
of a condition) into the regression models. The fasting
blood glucose level was entered into the regression models
in dichotomous form because the data were skewed. In a
separate regression analysis, the presence or absence of
MS was entered as a dichotomous variable. For all the re-
gression analyses performed, three models were generated:
model 1 contained only the MS indicators or the presence
of MS; model 2 contained the predictors in model 1 and
was adjusted for confounders such as age, ethnicity, smok-
ing status, TT and SHBG levels; model 3 contained the
predictors in model 2 and was further adjusted for BMI.
The significant value for all analysis performed was set at
p<0.05. Statistical Package for Social Sciences version 16
(SPSS Inc., Chicago, USA) was used to perform all the
analysis.Table 2 The comparison of SOS values among men with
different MS score
MS score Adjusted SOS value† (m/s) p-value
Mean Std. error






†The SOS values are adjusted for age, BMI, ethnicity, TT and SHBG levels of the
subjects.
Abbreviation: MS metabolic syndrome, SOS calcaneal speed of sound.Results
A total of 333 subjects with complete metabolic pheno-
types, calcaneal SOS, serum TT and SHBG data were eli-
gible for this study. After eliminating statistical outliers,
data from 309 subjects (age range 39-81 years; mean
54.05 years) were used in the analysis.
The prevalence of MS was 61.5% (190 subjects) in the
study population. Subjects with MS were significantly
older, heavier and had higher BMI compared to subjects
without MS (p<0.05). The WC, systolic BP, diastolic BP,
TG, FBS and SHBG levels of the MS subjects were sig-
nificantly higher compared to the non-MS subjects
(p<0.05). The HDL and TT levels of the MS subjects
were significantly lower compared to the non-MS sub-
jects (p<0.05). The two groups did not show significant
differences in height, calcaneal SOS, TC and LDL levels
(p>0.05). Smoking status and ethnicity were not related
to MS (p>0.05) (Table 1).There were no significant differences in SOS values
among subjects with different MS scores (0 to 5)
(p>0.05). Further adjustment for age, BMI, ethnicity, TT
and SHBG levels did not change the results (p>0.05)
(Table 2).
Table 4 Multiple linear regression results using indicators
of MS as dichotomous variables
Model 1 Model 2 Model 3
Predictor β p-value β p-value β p-value
Central adiposity 0.085 0.145 0.030 0.612 −0.008 0.901
Elevated BP −0.049 0.407 0.002 0.974 −0.056 0.357
Reduced HDL −0.029 0.612 −0.041 0.479 −0.007 0.911
Elevated TG 0.042 0.481 0.080 0.183 −0.049 0.394
Elevated FBG −0.072 0.223 −0.043 0.479 0.080 0.183
Model 1 includes the presence (0 = absence/1 = presence) of a metabolic
phenotype. Model 2 includes predictors in model 1, age, ethnicity, smoking
status, total testosterone and sex hormone-binding globulin levels. Model 3
includes predictors in model 2 and body mass index.
Abbreviation: BMI body mass index, BP blood pressure, FBG fasting blood
glucose, HDL high density lipoprotein cholesterol, MS metabolic syndrome, TG
triglycerides, WC waist circumference, β standardized coefficient of regression.
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tors of MS were not associated with calcaneal SOS in
unadjusted and adjusted models (p>0.05) (Table 3). Re-
analyzing the data in dichotomous forms (by considering
the presence or absence of the MS indicators) did not
change the results (p>0.05) (Table 4). The presence or
absence of MS was not associated with calcaneal SOS in
the study population (p>0.05) (Table 5).
Discussion
The current study found that calcaneal SOS did not dif-
fer significantly between Malaysian men with and with-
out MS. There was no significant difference in the value
of SOS among subjects with different MS scores. None
of the MS indicators or MS itself were significantly asso-
ciated with bone health in Malaysian men as assessed
using calcaneal QUS. The results of this study were
similar to the findings of Tseng et al. in elderly men and
women in Puli Township, Taiwan [20]. They assessed
the bone health of the study population using a similar
device to ours (Furuno CM-100 ultrasonometer) and
discovered that there was no significant difference in
SOS values between MS and non-MS subjects [20].
However, they found that an increase in TG and dia-
stolic BP and a decrease in WC were related to an in-
crease in SOS in men, which was not observed in this
study [20]. In the Camargo Cohort Study, Hernández
et al. found that none of the bone ultrasound indices
were significantly different between men with and with-
out MS [19]. They also reported no significant associa-
tions between any of the QUS indices and the individual
components of MS [19]. The presence of the MS was
not significantly related to previous fracture in their
study [19]. In a Chinese population, Zhao et al. foundTable 3 Multiple linear regression results using indicators
of MS as continuous variables
Model 1 Model 2 Model 3
Predictor β p-value β p-value β p-value
WC 0.069 0.267 0.026 0.702 −0.111 0.236
BPsys† −0.087 0.288 0.041 0.644 0.036 0.679
BPdia 0.113 0.167 0.020 0.815 0.007 0.935
HDL† 0.094 0.154 0.107 0.103 0.116 0.076
TG† 0.016 0.811 0.067 0.318 0.073 0.273
FBG* −0.072 0.228 −0.043 0.480 −0.051 0.397
†Indicates that log-transformed values are used in the analysis. *indicates that
dichotomous values (0=absence/1=presence of elevated FBG) are used in the
analysis.
Model 1 includes indicators of metabolic phenotype. Model 2 includes
predictors in model 1, age, ethnicity, smoking status, total testosterone and
sex hormone-binding globulin levels. Model 3 includes predictors in model 2
and body mass index.
Abbreviation: BMI body mass index, BP blood pressure, FBG fasting blood
glucose, HDL high density lipoprotein cholesterol, MS metabolic syndrome, TG
triglycerides, WC waist circumference, β standardized coefficient of regression.that there was no significant difference in estimated
BMD (eBMD; a composite bone ultrasound index gener-
ated by combining SOS and broadband attenuation of
sound; BUA) among male subjects with different MS
scores [23]. However, when grouped dichotomously,
eBMD was shown to be significantly higher in the MS
subjects compared to the non-MS subjects [23]. They
also found that an increase in FBG and a decrease in
WC and in HDL levels were associated with a significant
increase in BMD. These findings were not observed in
the current study [23].
The studies on the relationship between MS and BMD
in men also showed heterogeneous results. Kim et al. re-
ported that weight-adjusted femoral neck BMD was
lower in MS subjects compared to non-MS subjects of
both genders [18]. They also found that with increasing
MS components, the BMD of the subjects decreased sig-
nificantly [18]. In American adults, The Third National
Health and Nutrition Examination Survey revealed that
the femoral neck BMD was significantly higher in MS
subjects [17]. The researchers also found that with in-
creasing number in components of MS, the femoral
neck BMD of the subjects increased [17]. The positive
relationship between MS and BMD was also reported by
Boyanov et al. in Bulgarian men [16], Pasco et al. inTable 5 Multiple linear regression results using the
presence of MS as the dichotomous variable
Model 1 Model 2 Model 3
Predictor β p-value β p-value β p-value
MS* −0.043 0.451 0.005 0.934 −0.020 0.743
*Indicates that dichotomous values (0 = absence/1 = presence of metabolic
syndrome) are used in the analysis.
Model 1 includes the presence of metabolic syndrome. Model 2 includes
predictors in model 1, age, ethnicity, smoking status, total testosterone and
sex hormone-binding globulin levels. Model 3 includes predictors in model 2
and body mass index.
Abbreviation: BMI body mass index, BP blood pressure, FBG fasting blood
glucose, HDL high density lipoprotein cholesterol, MS metabolic syndrome, TG
triglycerides, WC waist circumference, β standardized coefficient of regression.
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men with type-2 diabetes [25]. Muhlen et al. reported an
interesting finding in Rancho Bernardo Study, in which
age-adjusted femoral neck BMD was significantly higher
in men with MS compared to men without MS [26].
After further adjustment for BMI, the relationship was
inverted and MS men were found to have lower BMD
[26]. The researchers concluded that the positive associ-
ation between BMD and MS was attributed to increased
BMI in MS subjects [26].
We suggest that the heterogeneity of the results is not
due to differences in methodology and site of measure-
ment. Studies using bone QUS at the heel and BMD at
the femoral neck had reported positive [17,24], negative
[18] and non-significant results [19,20]. Furthermore, in-
coherent findings were also obtained in populations of
similar background (Asian or Western). We suggest that
definition of MS, which is originally designated for pre-
dicting risk for cardiovascular diseases, is less useful in
predicting the risk for reduced bone health status in
men. In a meta-analysis, Xue et al. reported that the
overall association between MS and femoral neck BMD
was not significant, except in the Caucasians [27]. The
association between MS and spine BMD was stronger
[27]. However, it should be noted that this meta-analysis
considered only 11 studies using BMD.
In the current study, we utilized calcaneal SOS as the
bone health determinant. Calcaneal QUS was the only
bone QUS technique recommended by the International
Society of Clinical Densitometry because it was well
studied. [28]. The calcaneal bone is a weight-bearing
bone of the body [9,29]. Hence, it is sensitive to mechan-
ical loading. The calcaneal bone consists of more than
95% trabecular bone, which provides a high surface per
volume ration for the maximal exposure of bone cells to
humorous factors [30]. Hence, we suggest that it is a
suitable site to detect bone adaptive changes due to
mechanical and biochemical variations. Among the nu-
merous MS definitions, the harmonized criteria were
used because it is the most updated and suitable for use
in the Asian population. We adjusted the analysis in the
study for TT, SHBG and BMI because our previous stud-
ies showed that these factors were associated with both
MS and bone health status in Malaysian men [31-33].
Several limitations should be considered in the inter-
pretation of the results of this study. The study was con-
ducted in Klang Valley and involved Chinese and Malay
men only. Hence, the study population might not be
representative of the entire Malaysian population. The
bone ultrasonometer generated SOS as the bone health
determinant, while the other bone ultrasound index,
BUA, was not generated. However, a previous study had
shown that SOS was more related to BMD and elasticity
of the bone [34,35]. Subjects with MS were shown tohave higher level of proinflammatory cytokines [36],
which could potentially influence bone metabolism.
However, proinflammatory cytokine levels were not
measured in this study.
Conclusion
The bone health of middle-aged and elderly men in
Malaysia is not significantly associated with MS status
and indicators of MS. The usefulness of MS definition in
predicting bone health should be reconsidered. A longi-
tudinal study should also be performed to evaluate the
relationship between temporal bone loss and MS to con-
firm the findings.
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